<DOC>
	<DOC>NCT02664909</DOC>
	<brief_summary>This study is a double-blinded placebo-controlled clinical trial evaluating the efficacy of 1 gram of topically applied tranexamic acid vs. saline placebo for the reduction of transfusion following hip hemiarthroplasty surgery.</brief_summary>
	<brief_title>Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Femoral Neck Fractures</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Patients undergoing hip hemiarthroplasty surgery for a displaced femoral neck fracture History of hemophilia, history of deep vein thrombosis, history of pulmonary embolism, history of thrombophilia, history of chronic renal failure Patients with coronary ischemia (active or within the past calendar year), patients who have suffered a myocardial infarction, undergone percutaneous coronary intervention, undergone coronary artery bypass grafting, or undergone any revascularization procedure within the past calendar year Patients with active subarachnoid hemorrhage, acquired defective color vision, patients who sustained a pathologic fracture (fracture through a neoplastic lesion), or patients who are pregnant Patients with a known allergy to tranexamic acid Patients taking Warfarin, Dabigatran, Rivaroxaban, Apixaban, and Fresh Frozen Plasma</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hip Hemiarthroplasty</keyword>
	<keyword>Tranexamic Acid</keyword>
	<keyword>Topical</keyword>
	<keyword>Blood Transfusion</keyword>
</DOC>